Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protalix BioTherapeutics

1.35
-0.0450-3.23%
Volume:671.79K
Turnover:906.52K
Market Cap:107.47M
PE:28.03
High:1.40
Open:1.38
Low:1.32
Close:1.40
Loading ...

Barclays Keeps Their Hold Rating on PLUXEE N.V. (PLX)

TIPRANKS
·
09 Jun

Protalix BioTherapeutics Inc. Unveils Corporate Presentation Highlighting Expansion in Rare Disease Space

Reuters
·
14 May

Protalix BioTherapeutics Inc. to Present at H.C. Wainwright BioConnect Investor Conference in NYC

Reuters
·
14 May

Protalix BioTherapeutics Earnings Call: Growth Amid Challenges

TIPRANKS
·
10 May

Protalix BioTherapeutics Q1 EPS $(0.05) Misses $0.03 Estimate, Sales $10.11M Miss $21.60M Estimate

Benzinga
·
09 May

Press Release: Protalix BioTherapeutics Reports First Quarter 2025 Financial and Business Results

Dow Jones
·
09 May

PLUXEE N.V. (PLX) Receives a Buy from Citi

TIPRANKS
·
06 May

Protalix BioTherapeutics to Announce First Quarter 2025 Financial and Business Results on May 9, 2025

PR Newswire
·
05 May

Protalix files $100M mixed securities shelf

TIPRANKS
·
29 Apr

Top Penny Stocks To Watch In April 2025

Simply Wall St.
·
25 Apr

Kepler Capital Sticks to Its Buy Rating for PLUXEE N.V. (PLX)

TIPRANKS
·
24 Apr

Protalix BioTherapeutics' CFO Rubin to Leave

Dow Jones
·
24 Apr

UBS Reaffirms Their Hold Rating on PLUXEE N.V. (PLX)

TIPRANKS
·
23 Apr

PLUXEE N.V. (PLX) Gets a Hold from Barclays

TIPRANKS
·
22 Apr

Protalix BioTherapeutics And 2 Other Promising Penny Stocks

Simply Wall St.
·
26 Mar

Protalix BioTherapeutics to Present at the iAccess Alpha Virtual Best Ideas Spring Conference 2025

PR Newswire
·
24 Mar

Is Protalix BioTherapeutics (PLX) The High Growth Low Debt Stock to Invest in Now?

Insider Monkey
·
23 Mar

PLX: 2024 Results

Zacks Small Cap Research
·
18 Mar

Protalix BioTherapeutics Reports Record Revenue and Clinical Progress

TIPRANKS
·
18 Mar

Protalix BioTherapeutics Says With Debt Fully Repaid, It's Well-Positioned To Execute Strategy Through 2025 And Beyond

Benzinga
·
17 Mar